Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and Combined Effects of Interventions for ADHD
NCT05469386Phase 4Active, not recruiting
- Sponsor
- Florida International University
- Start
- Jun 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in attention deficit hyperactivity disorder (ADHD) (5 arms), sponsored by Florida International University. Primary endpoints: Behavioral frequency count of rule violations at 8 weeks, Seatwork completion at 8 weeks and 1 more. Started Jun 2022; status: active, not recruiting.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05469386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469386.